Genmab A/S
GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivaā¦ read more
Healthcare
Biotechnology
16 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$26.57
Price-2.96%
-$0.81
1Y
Price
Market Cap
$16.375b
Large
Price/Earnings 3y Avg5y Avg
17.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in DKK.+23.0%
EBITDA Margin+2.9%
Net Profit Margin+27.2%
Free Cash Flow Margin+23.0%
EBITDA Margin+2.9%
Net Profit Margin+27.2%
Free Cash Flow MarginRevenue
$23.728b
-33.5%
1y CAGR+3.6%
3y CAGR+20.8%
5y CAGREarnings
$6.143b
-62.7%
1y CAGR-0.9%
3y CAGR+20.4%
5y CAGREPS
$9.79
-61.5%
1y CAGR+0.8%
3y CAGR+21.7%
5y CAGRBook Value
$37.181b
$81.859b
Assets$44.678b
Liabilities$35.356b
DebtDebt to Assets
43.2%
6.9x
Debt to EBITDAFree Cash Flow
$7.329b
-41.4%
1y CAGR+20.6%
3y CAGR+35.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company